Early Discharge Protocols For Stem Cell Transplant Benefit Patients

Brian C. Betts, MD, Vice Chair of Strategic Initiatives for the Transplant & Cellular Therapy Program at Roswell Park Comprehensive Cancer Center, details the advantages of Roswell Park’s outpatient stem cell transplant program, which leverages an early discharge model to expand patient access and improve care delivery. Historically, stem cell transplant recipients remain hospitalized for 3 to 4 weeks postinfusion to monitor for acute complications. With improvements to safety and compatibility of donors with posttransplant cyclophosphamide to reduce severity of graft-vs-host disease and risk of nonrelapse mortality, patients are increasingly able to recover more quickly with the proper monitoring for complications.

the use of transplant has grown, and so Roswell Park has opened capacity by showing that patients can safely transition out of the inpatient setting as early as day +5 post-transplant, regardless of whether they underwent reduced-intensity or myeloablative conditioning regimens.

Patients residing within an hour's radius of the center are able to recover directly at home, and a local lodging infrastructure makes it possible to accommodate those who live further away. This accelerated discharge framework yields significant clinical, economic, and other benefits. By enabling patients to return to a familiar home environment sooner, the program substantially enhances quality of life, improves subjective well-being, and reduces healthcare expenditures, all while maintaining strong overall outcomes.

Beyond direct patient benefits, the early discharge framework fosters a robust collaborative care model with referring physicians, Betts explains. Discharging patients at day +5 facilitates seamless shared management, allowing referring doctors to engage with patients in outpatient clinic settings around key milestones, such as the day +30 bone marrow biopsy. This shared oversight streamlines communication and ensures coordinated execution when planning maintenance therapies or ongoing disease monitoring, establishing an efficient blueprint for modern stem cell transplant delivery.